ERBB2 and breast carcinoma: A significant advance has been achieved in determining treatment on the basis of subtypes of breast cancer, which are immunohistochemically classified based on the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [7, 8].